Supplemental Figure 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
ESR1m defective RSR signature shows prognostic association with disease specific survival (DSS) in the METABRIC ER+ breast cancer cohort Kaplan-Meier plot of high (top 50%) versus low (bottom 50%) of patients expressing the ESR1 mutant defective replication stress response signature in the METABRIC ER+ patient cohort. P-values were determined utilizing the log-rank test.
Fields of Study & Subjects
Breast Cancer Treatment Studies
Estrogen and related hormone effects
Advanced Breast Cancer Therapies
Publication details
- Publication date
- 2 April 2026
- Language
- EN